TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01088347

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mapatumumab
Description: Mapatumumab (10 or 30 mg/kg) intravenously on days 1, 22, and 45. In phase 2 the MTD established in phase 1 will be used.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Cisplatin 40 mg/m2 intravenously on days 8, 15, 22, 29, 36, and 45

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: Radiotherapy: a total dose of 45 Gy will be given in fractions of 1.8 Gy, five fractions per week (days 8-12, 15-19, 22-26, 29-33, and 36-40), by external beam irradiation by photon beam of at least 6 MV. After completing the five weeks of external beam irradiation, evaluation will take place to determine whether the boost can be given by brachytherapy. If brachytherapy is not feasible, the boost will be given by external beam irradiation to a total dose of 70.2 Gy in fractions of 1.8 Gy.
Study: NCT01289197

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Family Check Up
Description: Families in the intervention condition will be contacted by the parent consultant following the T1 and T2 assessments and be invited to participate in the Family Check-Up (FCU). The FCU intervention involves at least three sessions in which we expect both mother and child to participate in. First is the in-home family assessment. The second session involves rapport-building via an initial interview with the caregiver(s), referred to as the Get-to-Know-You visit, or for families already enrolled in an ongoing study, a Check-Back-In visit. The third is a Feedback Session during which the results of the assessment and initial interview are discussed with the caregiver, with attention focused on the caregiver's and child's readiness to change and the delineation of specific change options.
Study: NCT03258099

Intervention type: GENETIC
Intervention: detection of genotype
Description: detection of genotype by next generation sequencing

Intervention type: GENETIC
Intervention: detection of genotype
Description: detection of genotype by next generation sequencing
Study: NCT02867332

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-1 Knockout T Cells
Description: PD-1 Knockout T Cells and PD-1 wild-type T Cells will be made by Cell Biotech Co., Ltd. 2x107/kg T cells will be used for test group and comparable group separately.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IL-2
Description: Interleukin-2 (IL-2) will be given in the following 5 days after cell infusion, 720000 international unit（IU）/Kg/ day (if tolerant).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Interleukin-2 (IL-2) will be given in the following 5 days after cell infusion, 720000 international unit（IU）/Kg/ day (if tolerant).
Study: NCT02642159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab
Description: Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Statins
Description: Statins at stable dose without other LMT as clinically indicated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Statins
Description: Statins at stable dose without other LMT as clinically indicated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Pharmaceutical form: tablet Route of administration: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate
Description: Pharmaceutical form: tablet Route of administration: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotinic acid
Description: Pharmaceutical form: tablet Route of administration: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega-3 fatty acids
Description: Pharmaceutical form: tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antihyperglycemic Drug
Description: Insulin (injectable or inhaled) or other antihyperglycemic drugs as clinically indicated.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antihyperglycemic Drug
Description: Insulin (injectable or inhaled) or other antihyperglycemic drugs as clinically indicated.
Study: NCT04696926

Intervention type: OTHER
Intervention: Edwards Intuity TM Valve implantation
Description: aortic valve replacement with an Edwards Intuity TM bioprosthesis
Study: NCT00512395

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epidural analgesia (Duracain/Fentanyl/Naropin)
Description: naropin 0.3% or duracain 0.125% + Fentanyl via epidural catheter 4-12 ml/h
Study: NCT02339831

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CAMOPED
Description: Camoped given after surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPM passive motion device
Description: passive motion device given after surgery
Study: NCT02048228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: genotyping guided therapy Ticagrelor, Clopidogrel
Description: CYP2C19\*2 carriers will be given 90 mg ticagrelor twice daily, and non-carriers and patients in the standard treatment group will be given 75 mg clopidogrel daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard therapy clopidogrel
Description: All patients will be administrated with clopidogrel 75 mg daily for 5 consecutive days.
Study: NCT01934049

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hip arthroplasty
Description: Every patient with femoral neck fractures must undergo hip hemi-arthroplasty.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: hip arthroplasty
Description: Every patient with femoral neck fractures must undergo hip hemi-arthroplasty.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Total Intravenous Anesthesia and Peripheral nerve blocks
Description: Every patient receives Peripheral nerve blocks and Total Intravenous Anesthesia with propofol
Study: NCT01283412

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo (saline) iv. during the operation and stoped 30min before end of the surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine 0.1\~0.2ug/kg/h iv. during the operation, and stoped 30min before end of surgery
Study: NCT01274091

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PUFA-diet
Description: Diets will contain 30% of energy as fat, 18% as protein and 52% as carbohydrates: polyunsaturated fatty acid diet (PUFA) will have P/S ratio 1.0.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SAFA-diet
Description: Diets will contain 30% of energy as fat, 18% as protein and 52% as carbohydrates: Saturated fatty acid diet (SAFA) will polyunsaturated/saturated (P/S) ratio of 0.3.
Study: NCT01952626

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palonosetron
Description: intravenous injection
Study: NCT00707031

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lixisenatide (AVE0010)
Description: Self administered by subcutaneous injections once daily within the hour preceding breakfast.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pen auto-injector

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exenatide
Description: Self administered by subcutaneous injections twice daily within the hour preceding breakfast and within the hour preceding dinner.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prefilled pen injector
Study: NCT01934049

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Total Intravenous Anesthesia and Peripheral nerve blocks
Description: Every patient receives Peripheral nerve blocks and Total Intravenous Anesthesia with propofol
Study: NCT04000425

Intervention type: COMBINATION_PRODUCT
Intervention: AVENIO ctDNA surveillance kit
Description: AVENIO circulating tumor DNA (ctDNA) Analysis Kits is a portfolio of three next-generation sequencing (NGS) liquid biopsy assay kits for oncology research: the AVENIO ctDNA Targeted Kit, Expanded Kit and Surveillance Kit.
Study: NCT00707031

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.
Study: NCT01156961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 10 mg/kg iv every 2 weeks or 15 mg/kg iv every 3 weeks
Study: NCT04360733

Intervention type: OTHER
Intervention: Blood draw
Description: serial blood draw and subsequent deep immune phenotyping analysis, (ii.) immune activation assays, (iii.) transcriptome and (iv.) epigenome analysis in an overarching (v.) bioinformatics data analysis
Study: NCT02627014

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home physical therapy
Description: once a day: 15 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy in cervical region
Description: 6 treatments: 2 treatments for week~1 treatment = 30 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home physical therapy in cervical region
Description: once a day: 15 minutes
Study: NCT04556110

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perindopril tert-Butylamine tablets （ Produced by Haisco）
Description: The trial was divided into four cycles, between of each cycle with a 14-day wash-out period.In the first cycle，subjects in experimental group took the test preparation Perindopril tert-butylamine after meal, and subjects in control group took the reference preparation ACERTIL® after meal; In the second cycle subjects in experimental group took the reference preparation ACERTIL® after meal , the trial preparation perindopril tert-butylamine was taken orally after meals for the subjects in control group ; the order of taking the medicines for the subjects in the third cycle was the same as that in the first cycle, and the taking order of the subjects in the fourth cycle was the same as that in the second cycle. A single oral administration was used for the four cycles, and the dose was 4 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perindopril tert-Butylamine tablets（ACERTIL®）
Description: The trial was divided into four cycles, between of each cycle with a 14-day wash-out period.In the first cycle，subjects in experimental group took the test preparation Perindopril tert-butylamine after meal, and subjects in control group took the reference preparation ACERTIL® after meal; In the second cycle subjects in experimental group took the reference preparation ACERTIL® after meal , the trial preparation perindopril tert-butylamine was taken orally after meals for the subjects in control group ; the order of taking the medicines for the subjects in the third cycle was the same as that in the first cycle, and the taking order of the subjects in the fourth cycle was the same as that in the second cycle. A single oral administration was used for the four cycles, and the dose was 4 mg.
Study: NCT00979160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Starting dosage 20mg once daily, that can be escalated up to 100mg once daily. Patient will remain on treatment for 12 months.
Study: NCT05517512

Intervention type: DIAGNOSTIC_TEST
Intervention: Estimation of Protein 13
Description: Serum biomarkers' levels were measured using enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturer's instructions and were read using a 96 well microplate ELISA reader (Dynatech. MR 7000)~1. Human placental growth factor (PLGF) was measured with the enzyme-linked immunoassay (ELISA) kit (catalog no. DPG00 SPG00 PDPG00, R\&D Systems Inc., Minneapolis, USA) by quantitative sandwich enzyme immunoassay technique (20).~2. Human soluble fms-like tyrosine kinase-1 (sFlt-1) was measured with the enzyme-linked immunoassay (ELISA) kit (catalog no. MBS601616, MyBioSource, Inc., California, San Diego, USA) by quantitative sandwich enzyme immunoassay technique (21).~3. Human pregnancy protein 13 was measured with the enzyme-linked immunoassay (ELISA) kit (catalog no. ab100553, Abcam Inc., Cambridge, USA) by quantitative sandwich enzyme immunoassay technique (22).

Intervention type: DIAGNOSTIC_TEST
Intervention: Estimation of Protein 13
Description: Serum biomarkers' levels were measured using enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturer's instructions and were read using a 96 well microplate ELISA reader (Dynatech. MR 7000)~1. Human placental growth factor (PLGF) was measured with the enzyme-linked immunoassay (ELISA) kit (catalog no. DPG00 SPG00 PDPG00, R\&D Systems Inc., Minneapolis, USA) by quantitative sandwich enzyme immunoassay technique (20).~2. Human soluble fms-like tyrosine kinase-1 (sFlt-1) was measured with the enzyme-linked immunoassay (ELISA) kit (catalog no. MBS601616, MyBioSource, Inc., California, San Diego, USA) by quantitative sandwich enzyme immunoassay technique (21).~3. Human pregnancy protein 13 was measured with the enzyme-linked immunoassay (ELISA) kit (catalog no. ab100553, Abcam Inc., Cambridge, USA) by quantitative sandwich enzyme immunoassay technique (22).

Intervention type: DIAGNOSTIC_TEST
Intervention: Estimation of Protein 13
Description: Serum biomarkers' levels were measured using enzyme-linked immunosorbent assay (ELISA) kits according to the manufacturer's instructions and were read using a 96 well microplate ELISA reader (Dynatech. MR 7000)~1. Human placental growth factor (PLGF) was measured with the enzyme-linked immunoassay (ELISA) kit (catalog no. DPG00 SPG00 PDPG00, R\&D Systems Inc., Minneapolis, USA) by quantitative sandwich enzyme immunoassay technique (20).~2. Human soluble fms-like tyrosine kinase-1 (sFlt-1) was measured with the enzyme-linked immunoassay (ELISA) kit (catalog no. MBS601616, MyBioSource, Inc., California, San Diego, USA) by quantitative sandwich enzyme immunoassay technique (21).~3. Human pregnancy protein 13 was measured with the enzyme-linked immunoassay (ELISA) kit (catalog no. ab100553, Abcam Inc., Cambridge, USA) by quantitative sandwich enzyme immunoassay technique (22).
Study: NCT05720481

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Full mouth Scaling and root planing
Description: patients were treated with full mouth Scaling and root planing

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quadrant Scaling and root planing
Description: patients were treated with quadrant Scaling and root planing
Study: NCT00606684

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GW642444 6.25
Description: GW642444 6.25

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GW642444 3mcg
Description: once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GW642444 12.5mcg
Description: GW642444 12.5mcg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GW642444 25mcg
Description: GW642444 25mcg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GW642444 50mcg
Description: GW642444 50mcg

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT03979209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Mometasone Rinse
Description: Nasal irrigation twice a day (BID) of assigned dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Mometasone Rinse
Description: Nasal irrigation twice a day (BID) of assigned dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Mometasone Rinse
Description: Nasal irrigation twice a day (BID) of assigned dose.
Study: NCT01465776

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: preventative dietary intervention
Description: lyophilized black raspberries(LBR) administration: 3 LBR troche lozenges (dissolved in mouth), 4 times/day beginning at minimum of 24 hrs following biopsy until night before surgery
Study: NCT03875183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INL1
Description: Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INL1
Description: Capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INL1
Description: Capsules

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules
Study: NCT02143947

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Maximal Arch Subtalar Stabilization
Description: Custom made semi-rigid thermoplastic heel cup extending to the base of the metatarsals with a full foot length 3.0mm thick EVA and ultra-suede top cover

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Full Contact Orthosis
Description: The Full Contact orthosis is constructed from a 5/32 blue polypropylene with posting material comprised of white polypropylene.
Study: NCT01156961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 90 mg/m2 iv days 1, 8 and 15 of every 28-day cycle or 175 mg/m2 iv day 1 of each 21-day cycle
Study: NCT04633512

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ActivSight
Description: Use of ActivSight in patients undergoing laparoscopic or robot assisted intestinal anastomoses and patients undergoing laparoscopic or robot assisted cholecystectomy.
Study: NCT02393950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ODM-106
Description: Single oral escalating doses of ODM-106 will be administered. Each subject will participate in 4 study periods and will therefore receive 3 single doses of ODM-106 and one single dose of placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single oral escalating doses of ODM-106 will be administered. Each subject will participate in 4 study periods and will therefore receive 3 single doses of ODM-106 and one single dose of placebo.
Study: NCT04360733

Intervention type: OTHER
Intervention: Blood draw
Description: serial blood draw and subsequent deep immune phenotyping analysis, (ii.) immune activation assays, (iii.) transcriptome and (iv.) epigenome analysis in an overarching (v.) bioinformatics data analysis

Intervention type: OTHER
Intervention: Blood draw
Description: serial blood draw and subsequent deep immune phenotyping analysis, (ii.) immune activation assays, (iii.) transcriptome and (iv.) epigenome analysis in an overarching (v.) bioinformatics data analysis

Intervention type: OTHER
Intervention: Blood draw
Description: serial blood draw and subsequent deep immune phenotyping analysis, (ii.) immune activation assays, (iii.) transcriptome and (iv.) epigenome analysis in an overarching (v.) bioinformatics data analysis
Study: NCT03610126

Intervention type: PROCEDURE
Intervention: volume controlled ventilation
Description: the patients will be ventilated by volume controlled ventilation after insertion of the BASKA laryngeal mask airway

Intervention type: PROCEDURE
Intervention: pressure controlled ventilation
Description: the patients will be ventilated by pressure controlled ventilation after insertion of the BASKA laryngeal mask airway
Study: NCT00941330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exemestane
Description: 25 mg daily by mouth for 6 to 12 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel (75 mg/m²) into a vein once every 3 weeks for 6 cycles (6 times in about 24 weeks).
Study: NCT04391673

Intervention type: BEHAVIORAL
Intervention: Vestibular rehabilitation
Description: Vestibular rehabilitation (treatment as usual).
Study: NCT00941330

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytoxan
Description: Cytoxan (600 mg/m²) into a vein once every 3 weeks for 6 cycles (6 times in about 24 weeks).
Study: NCT01944904

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: The placebo is identical in appearance to the XOS and contains 505mg maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: XOS 2.8
Description: 2.8g XOS is white or off-white crystalline substance and contains 500mg XOS 70P and 20mg maltodextrin
Study: NCT03606330

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac imaging tests
Description: * 2D transthoracic echocardiography~* 128-multislice CT coronary angiography with the evaluation of: epicardial fat volume, plaque burden, total and local calcium score, markers for lesion severity; morphological plaque characteristics; plaque components evaluated via volumetric and planimetric units; markers of plaque vulnerability (necrotic core, low attenuation plaque, spotty calcification, napkin ring sign, positive remodeling).~* Shear stress evaluation via computational fluid dynamics.~* Intracoronary imaging techniques: IVUS and OCT.

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac imaging tests
Description: * 2D transthoracic echocardiography~* 128-multislice CT coronary angiography with the evaluation of: epicardial fat volume, plaque burden, total and local calcium score, markers for lesion severity; morphological plaque characteristics; plaque components evaluated via volumetric and planimetric units; markers of plaque vulnerability (necrotic core, low attenuation plaque, spotty calcification, napkin ring sign, positive remodeling).~* Shear stress evaluation via computational fluid dynamics.~* Intracoronary imaging techniques: IVUS and OCT.

Intervention type: DIAGNOSTIC_TEST
Intervention: Venous blood sample collection
Description: Venous blood sample collection during the acute coronary event for evaluation of serum levels of hsCRP, IL-6, matrixmetalloproteases MMP9, Adhesion molecules (VCAM, ICAM), alfa tumour necrosis factor, hs-cTnI, NTproBNP

Intervention type: DIAGNOSTIC_TEST
Intervention: Venous blood sample collection
Description: Venous blood sample collection during the acute coronary event for evaluation of serum levels of hsCRP, IL-6, matrixmetalloproteases MMP9, Adhesion molecules (VCAM, ICAM), alfa tumour necrosis factor, hs-cTnI, NTproBNP